Medicine
Kyprolis 10 mg/5 mL powder for injection
Kyprolis 10 mg/5 mL powder for injection is a prescription medicine containing Carfilzomib for intravenous use, marketed by Onyx Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Unopened vials should be stored refrigerated 2°C to 8°C (36°F to 46°F). Retain…
Key facts
- Active ingredient (INN)
- Carfilzomib
- Brand
- Kyprolis
- Strength
- 10 mg/5 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial and 3 more
- Marketing authorisation holder
- Onyx Pharmaceuticals
- Manufacturer
- Onyx Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Unopened vials should be stored refrigerated 2°C to 8°C (36°F to 46°F). Retain in original package to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX45 Carfilzomib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 July 2012
- Identifiers
- RxCUI 1806934, 1806937, 1806940 +3DailyMed set ID ea66eb30-e665-4693-99a1-a9d3b4bbe2d6NDC 76075-101, 76075-103, 76075-102Application NDA202714
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 30 mL in 1 vial, single-use | 76075-101-01 | Onyx Pharmaceuticals | 20 July 2012 |
| 1 vial, single-use in 1 carton / 30 mL in 1 vial, single-use | 76075-101-21 | Onyx Pharmaceuticals | 1 October 2025 |
| 1 vial, single-dose in 1 carton / 15 mL in 1 vial, single-dose | 76075-102-01 | Onyx Pharmaceuticals | 15 July 2016 |
| 1 vial, single-dose in 1 carton / 15 mL in 1 vial, single-dose | 76075-102-21 | Onyx Pharmaceuticals | 1 October 2025 |
| 1 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 76075-103-01 | Onyx Pharmaceuticals | 23 May 2018 |
| 1 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 76075-103-21 | Onyx Pharmaceuticals | 1 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Carfilzomib is a proteasome inhibitor indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, among other approved uses. MedsAcross supplies Carfilzomib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CarfilzomibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KYPROLIS prescribing information (Onyx Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Kyprolis: European public assessment report (EPAR) · European Medicines Agency
Need Kyprolis 10 mg/5 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.